<DOC>
	<DOCNO>NCT02376868</DOCNO>
	<brief_summary>Assess repeatability agreement Optic Disc Parameters , Retinal Nerve Fiber Layer ( RNFL ) Thickness , Full Retinal Thickness , Ganglion Cell Thickness Maestro iVue OCT device .</brief_summary>
	<brief_title>Maestro Agreement Precision Study II</brief_title>
	<detailed_description />
	<mesh_term>Retinal Diseases</mesh_term>
	<criteria>Inclusion Criteria Normal Group 1 . Subjects 18 year age old date inform consent 2 . Subjects able understand write informed consent willing participate evidence signing inform consent 3 . Subjects present site normal eye ( eye without pathology ) 4. lOP &lt; =21 mmHg bilaterally 5 . BCVA 20/40 better ( eye ) 6 . Both eye must free eye disease Exclusion Criteria Normal Group 1 . Subjects previously enrol either Maestro AP study Maestro2 study 2 . Subjects unable tolerate ophthalmic imaging 3 . Subject ocular medium sufficiently clear obtain acceptable OCT image 4 . HFA visual field ( 242 Sita Standard , white white ) result unreliable ( base manufacturer 's recommendation ) , define fixation loss &gt; 20 % false positives &gt; 33 % , false negative &gt; 33 % 5 . Visual field defect consistent glaucomatous optic nerve damage least one follow two finding : 1 . On pattern deviation ( PD ) , exist cluster 3 point expect location visual field depress 5 % level , least 1 depressed 1 % level ; 2 . Glaucoma hemifield test `` outside normal limit . '' 6 . Presence ocular pathology except cataract 7 . Narrow angle 8 . History leukemia , dementia multiple sclerosis 9 . Concomitant use hydroxychloroquine chloroquine Inclusion Criteria Glaucoma Group 1 . Subjects 18 year age old date inform consent 2 . Subjects able understand write informed consent willing participate evidence signing inform consent 3 . BCVA 20/40 good study eye 4 . Visual field defect consistent glaucomatous optic nerve damage base least one follow two finding : 1 . On pattern deviation ( PD ) , exist cluster 3 point expect location visual field depress 5 % level , least 1 depressed 1 % level ; 2 . Glaucoma hemifield test `` outside normal limit . '' 5 . Glaucomatous optic nerve damage evidence follow optic disc retinal nerve fiber layer structural abnormality : 1 . Diffuse thinning , focal narrowing , notch optic disc rim , especially inferior superior pole without disc hemorrhage ; 2 . Localized abnormality peripapillary retinal nerve fiber layer , especially inferior superior pole ; 3 . Optic disc neural rim asymmetry two eye consistent loss neural tissue Exclusion Criteria Glaucoma Group 1 . Subjects previously enrol either Maestro AP study Maestro2 study 2 . Subjects unable tolerate ophthalmic imaging 3 . Subject ocular medium sufficiently clear obtain acceptable OCT image 4 . HFA visual field ( 242 Sita Standard , white white ) result unreliable , defined fixation loss &gt; 20 % false positives &gt; 33 % , false negative &gt; 33 % study eye 5 . Presence ocular pathology except glaucoma study eye 6 . History leukemia , dementia multiple sclerosis 7 . Concomitant use hydroxychloroquine chloroquine Inclusion Criteria Retina Disease Group 1 . Subjects 18 year age old date inform consent 2 . Subjects able understand write informed consent willing participate evidence signing inform consent 3 . Subjects present site retinal disease 4. lOP &lt; = 21 mmHg study eye 5 . BCVA 20/400 good study eye 6 . Diagnosis type retinal pathology investigator , may include , limited : Macular Degeneration , Diabetic Macular Edema , Diabetic Retinopathy , Macular Hole , Epiretinal Membrane , Cystoid Macula Edema , others Exclusion Criteria Retinal Disease Group 1 . Subjects previously enrol either Maestro AP study Maestro2 study 2 . Subjects unable tolerate ophthalmic imaging 3 . Subject ocular medium sufficiently clear obtain acceptable OCT image 4 . Presence glaucoma ocular pathology Retinal pathology ( e.g. , cornea pathology ) study eye 5 . Narrow angle study eye 6 . History leukemia , dementia multiple sclerosis 7 . Concomitant use hydroxychloroquine chloroquine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>